RecruitingNCT06860438

Observational Study About the Use of Perfusion Index to Use Vasopressor in Sepsis

Can Perfusion Index Indicate the Need of Vasopressor in ICU Patients with Sepsis and Septic Shock, Prospective Observational Study


Sponsor

Ain Shams University

Enrollment

40 participants

Start Date

Aug 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

In this thesis we will use the current state of knowledge that PI can provide a reliable information about the state of peripheral microcirculation during the state of sepsis and septic shock in ICU patients and that can interfere with the timing of starting vasopressor treatment in sepsis and septic shock


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • \- All ICU patients with clinically suspected sepsis and septic shock ( signs include fever hypotension oliguria and confusion combined with culture results showing infection .Septic shock is a subset of sepsis involves persistent hypotension (mean arterial pressure ≥ 65 mm Hg, and a serum lactate level \> 18 mg/dL \[2 mmol/L)not responding to fluid resuscitation ) .

Exclusion Criteria6

  • Pregnant females
  • Patients on vasopressor or positive inotropic drugs
  • Patients with hypothermia (defined as central temperature \<35°C).
  • Patient with impairment of upper extremity circulation,(such as those who underwent radial artery harvesting for coronary artery bypass grafting or had suspected occlusion of the radial artery prior to surgery,)
  • Patients had undergone an operation that involved the large arteries of the aortic arch.
  • Patients with atherosclerosis .

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVasoconstrictor Agents

vasopressor agents will be started in patients with sepsis who will not improved using the resuscitation fluids


Locations(1)

faculty of medicine Ain Shams University

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06860438


Related Trials